Subject has significantly impaired hepatic function at the 'End of Treatment visit of their Core Study or at Visit 1 if re-assessed alanine aminotransferase ALT 5 x upper limit of normal ULN or total bilirubin TBL 2 x ULN OR ALT or aspartate aminotransferase AST 3 x ULN and TBL 2 x ULN or international normalized ratio INR 1.5 This criterion can only be confirmed once the laboratory results are available subjects that entered the study and are later found not to meet this criterion should be withdrawn from the study 